This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Idiopathic Thrombocytopenic Purpura
and you are
over 18
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The purpose of this study is to further evaluate the effects that eltrombopag has on platelets in subjects with chronic ITP. Eltrombopag is approved by the Food and Drug Administration (FDA) for the treatment of low platelets in patients with chronic ITP. It is being further studied by GlaxoSmithKline in other conditions associated with low platelets. This research study is being done because eltrombopag has been shown to increase platelet counts in a different way than other therapies for ITP. The investigators want to further study how eltrombopag affects subjects and their platelets to determine how the study drug should best be used in ITP treatment.

Provided treatments

  • Drug: Promacta (eltrombopag)
Tris trial is registered with FDA with number: NCT00902018. The sponsor of the trial is Weill Medical College of Cornell University and it is looking for 12 volunteers for the current phase.
Official trial title:
The Effect of Eltrombopag on Platelet Survival: the Role of the B-cell Lymphoma Extra Large (BcL-xL) Pathway